Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Mezigdomid (CC-92480) nach Idecabtagene Vicleucel bei der Behandlung von Patienten mit rezidiviertem multiplem Myelom

6. November 2026 aktualisiert von: City of Hope Medical Center

Eine Phase-1-Studie zu Mezigdomid (CC-92480) und Dexamethason nach Idecabtagene Vicleucel bei rezidiviertem multiplem Myelom

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.

Studienübersicht

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To evaluate the safety and tolerability of mezigdomide (CC-92480) given post idecabtagene vicleucel when administered as a continued therapy.

SECONDARY OBJECTIVES:

I. To evaluate the anti-tumor activity of mezigdomide (CC-92480) when administered post idecabtagene vicleucel.

II. To determine the persistence of CAR T cells at day 90 (D90), day 180 (D180), and day 365 (D365) after start of mezigdomide (CC-92480) therapy.

EXPLORATORY OBJECTIVES:

I. To assess levels of serum BCMA monthly at day 1 of every cycle. II. To assess the effects of mezigdomide (CC-92480) on non-cancer immune cells in the peripheral blood and bone marrow samples.

OUTLINE: This is a dose-escalation study of mezigdomide.

Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide orally (PO) on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT) during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 30 days, every 3 months within 1 year of start of treatment, and then every 6 months until progression or for up to 2 years.

Studientyp

Interventionell

Einschreibung (Geschätzt)

15

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • City of Hope Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Age: >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) =< 2

  • Diagnosis of multiple myeloma

  • Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody

  • Receipt of commercially available idecabtagene vicleucel (Abecma) according to FDA approved US Prescribing Information. Note: Patients who received non-conforming Abecma who were originally prescribed Abecma according to the FDA approved label may be considered for inclusion per the investigators discretion. Subject must be between day 30 and day 90 post receipt of idecabtagene vicleucel

  • Subject must have experienced at least a stable disease in response to idecabtagene vicleucel

  • Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy, including idecabtagene vicleucel

  • Absolute neutrophil count (ANC) >= 1,500/mm^3 without the use of filgrastim in the previous 3 days (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Platelets >= 75,000/mm^3 without platelet transfusion in the previous 3 days. (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has known Gilbert's disease) (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Aspartate aminotransferase (AST) =< 3 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Alanine transaminase (ALT) =< 3 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Alkaline phosphatase =< 5 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

    • Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met
  • Oxygen saturation > 92% on room air (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • Agreement by females of childbearing potential and males to follow the guidelines of the mezigdomide (CC-92480) pregnancy prevention plan

Exclusion Criteria:

  • Prior exposure to mezigdomide (CC-92480)
  • Current or planned use of other therapies other than mezigdomide (CC-92480)
  • Patients who are currently receiving or likely to require systemic immunosuppressive therapy. Physiologic replacement of steroids (=< 5.0 mg/day prednisone or equivalent) is allowed
  • Concomitant use of CYP3A4/5 inhibitors and inducers
  • Concomitant use of proton pump inhibitors
  • Evidence of relapse as evaluated by the treating physician or study investigator
  • Active central nervous system involvement
  • Ongoing toxicities associated with cytokine release syndrome (CRS) or Immune effector cell-associated neurotoxicity syndrome (ICANS) from CAR T cell therapy
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • Coronavirus disease 2019 (COVID-19) positive, as assessed by a polymerase chain reaction (PCR) test or active uncontrolled infections (defined as active antibiotic use within 7 days of starting the investigational drug)
  • If human immunodeficiency virus (HIV) positive: CD4+ T cell count < 200
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment (mezigdomide)

Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide PO on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.

Undergo blood sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Undergo CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)

Undergo bone marrow aspiration

Undergo PET/CT

Andere Namen:
  • Medizinische Bildgebung, Positronen-Emissions-Tomographie
  • HAUSTIER
  • PET-Scan
  • Positronen-Emissions-Tomographie-Scan
  • Positronen-Emissions-Tomographie
  • Protonen-Magnetresonanzspektroskopische Bildgebung
  • Pt
  • Positronen-Emissions-Tomographie (Verfahren)

Receive PO

Andere Namen:
  • BMS-986348
  • CC-92480
  • BMS 986348
  • BMS986348
  • CC 92480
  • CELMoD CC-92480
  • Cereblon E3-Ligase-Modulationsmedikament CC-92480
  • Cereblon E3 Ubiquitin-Ligase-Modulator CC-92480
  • Cereblon-Modulator CC-92480

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of adverse events
Zeitfenster: Up to 2 years

Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0). Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.

Up to 2 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Gesamtüberleben
Zeitfenster: Vom ersten Tag der Behandlung bis zum Zeitpunkt des Todes aus irgendeinem Grund, geschätzt bis zu 2 Jahre
Vom ersten Tag der Behandlung bis zum Zeitpunkt des Todes aus irgendeinem Grund, geschätzt bis zu 2 Jahre
Zeit für Fortschritt
Zeitfenster: Vom ersten Tag der Behandlung bis zur ersten Beobachtung eines Fortschreitens der Krankheit oder eines krankheitsbedingten Todes, bewertet bis zu 2 Jahre
Vom ersten Tag der Behandlung bis zur ersten Beobachtung eines Fortschreitens der Krankheit oder eines krankheitsbedingten Todes, bewertet bis zu 2 Jahre
Overall response rate
Zeitfenster: Up to 2 years

Will be defined as the proportion of subjects with a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR), or partial response (PR), as determined by the investigator according to standard International Myeloma Working Group (IMWG) response criteria.

Up to 2 years
Complete response rate
Zeitfenster: Up to 2 years

Will be defined as the proportion of patients meeting the criteria CR or sCR.

Up to 2 years
Progression free survival
Zeitfenster: From first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 2 years

Will be determined by the investigator according to standard IMWG response criteria.

From first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 2 years
Duration of response
Zeitfenster: From first response documented until disease progression, assessed up to 2 years

Will be determined by the investigator according to standard IMWG response criteria.

From first response documented until disease progression, assessed up to 2 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Murali Janakiram, City of Hope Medical Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. April 2024

Primärer Abschluss (Geschätzt)

9. Februar 2027

Studienabschluss (Geschätzt)

9. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

15. September 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. September 2023

Zuerst gepostet (Tatsächlich)

21. September 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren